(Reuters) -An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
The drug, vepdegestrant, was tested in patients with a type of advanced breast cancer whose disease progressed following prior treatment.
The drug met the main goal of progression-free survival in patients whose cancer expressed a certain type of mutation, but failed to show statistically significant improvement in the intent-to-treat population, the companies said on Tuesday.
Shares of Arvinas slumped 37% to $11.06 in premarket trading.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Comments